Corvia Medical, Inc., is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The IASD System II is the worldᅢᄁ¬ツᆲ¬トᄁs first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Capital. In the United States, the IASD System is an investigational device and not available for commercial distribution or sale.
For more information, please visit http://www.corviamedical.com